Table 4 Details of 12 followed up patients with BS
From: Deficiency of peripheral CLA+ Tregs and clinical relevance in Behcet’s syndrome
Patient | Sex/Age (year) | Disease duration (month) | Clinical manifestations within 4 weeks before enrollment | Treatment before enrollment | Treatment after enrollment | Follow-up time (month) | BDCAF |
|---|---|---|---|---|---|---|---|
1 | Male/68 | 492 | O, P, A, AA | GC | GC, Tocilizumab | 17 | 4——1 |
2 | Female/46 | 276 | O, GU, E, A, N | GC | GC, Tocilizumab | 11 | 5——4 |
3 | Male/45 | 120 | O, GU, A, T | — | GC, MMF | 5 | 4——3 |
4 | Male/28 | 120 | O, E | GC | GC, MMF, HCQ | 7 | 2——1 |
5 | Male/29 | 180 | O, P, A, G, N | HCQ | TAC, HCQ | 11 | 5——3 |
6 | Male/40 | 240 | O, GU, U, N | GC | GC, Rituximab | 4 | 4——3 |
7 | Female/37 | 168 | O, GU, E, A, G | GC | GC, Golimumab, MMF, HCQ | 7 | 6——2 |
8 | Female/28 | 28 | O, G, N | Thalidomide | GC, Thalidomide, MMF, Colchicine | 11 | 3——2 |
9 | Female/33 | 204 | O, GU | — | GC | 21 | 2——1 |
10 | Male/33 | 120 | O, N | — | Thalidomide | 12 | 2——1 |
11 | Male/21 | 60 | O, GU, E, T | GC | GC | 38 | 4——2 |
12 | Male/38 | 240 | O, GU, P | — | Thalidomide | 6 | 3——0 |